Patents whose numbers are in italics have been extended under 35 USC 156. Unless otherwise noted, all expiration dates include applicable Sec. 156 and pediatric (PED) extensions.
Pat No. Expir. Patent Title, Tradenames & Claim Types 6716602 Oct 31, 2021 Metabolic rate shifts in fermentations expressing recombinant proteins
Claim Types: Process
Lucentis (Injection) (Intravitreal)6805686 May 6, 2023 Autoinjector with extendable needle protector shroud
Claim Types: Device; Method of administration
Humira (Injection) (Subcutaneous)6828121 Jul 7, 2022 Bacterial host strains
Claim Types: Bacterial strain; Process
Lucentis (Injection) (Intravitreal)6921659 Oct 16, 2023 Protease-deficient cells
Claim Types: Bacterial strain; Process
Lucentis (Injection) (Intravitreal)7070959 Jun 16, 2023 Modified chimeric polypeptides with improved pharmacokinetic properties
Claim Types: Nucleic Acid; Expression Vector; Process
Eylea (Injection) (Intravitreal)7157276 Jun 21, 2024 Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Claim Types: Process
Tysabri (Injection) (Intravenous)7485704 Mar 7, 2025 Reducing protein A leaching during protein A affinity chromatography
Claim Types: Process
Avastin (Injection) (Intravenous)7759117 Jun 21, 2024 Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Claim Types: Process
Tysabri (Injection) (Intravenous)8124350 Aug 2, 2027 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)8231876 Apr 4, 2027 Purified antibody composition
Claim Types: Product-by-process; Drug in a container
Humira (Injection) (Subcutaneous)8318416 Jan 20, 2031 Nutrient monitoring and feedback control for increased bioproduct production
Claim Types: Process
Tysabri (Injection) (Intravenous)8383773 Dec 13, 2023 Protein product and method for reducing biomass-biomass interactions
Claim Types: Product-by-process
Lucentis (Injection) (Intravitreal)8420081 Jan 13, 2030 Antibody formulations and methods of making same
Claim Types: Formulation; Product-by-process; Device; Drug in a container; Process
Humira (Injection) (Subcutaneous)8460895 Mar 10, 2029 Method for producing recombinant proteins with a constant content of pCO.sub.2 in the medium
Claim Types: Process
Avastin (Injection) (Intravenous)8512983 Jan 3, 2031 Production of proteins in glutamine-free cell culture media
Claim Types: Process; Cell culture medium
Avastin (Injection) (Intravenous)8574869 Jul 7, 2028 Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Avastin (Injection) (Intravenous); Lucentis (Injection) (Intravitreal)8663945 Sep 13, 2027 Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
Claim Types: Process
Humira (Injection) (Subcutaneous)8708968 Jan 24, 2032 Removal of needle shields from syringes and automatic injection devices
Claim Types: Device
Humira (Injection) (Subcutaneous)8715664 Jul 24, 2027 Use of human TNF.alpha. antibodies for treatment of erosive polyarthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8808700 May 16, 2026 Use of TNF alpha inhibitor for treatment of erosive polyarthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8809049 May 22, 2031 Methods for producing mammalian cells
Claim Types: Process
Tysabri (Injection) (Intravenous)8871449 Apr 12, 2026 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)8883156 Apr 4, 2027 Purified antibody composition
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8889136 Oct 9, 2027 Multiple-variable dose regimen for treating TNF.alpha.-related disorders
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8895009 Apr 4, 2027 Purified antibody composition
Claim Types: Formulation
Humira (Injection) (Subcutaneous)8906372 Apr 4, 2027 Purified antibody composition
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8906373 Jul 18, 2023 Use of TNF-alpha inhibitor for treatment of psoriasis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8906646 Sep 13, 2027 Fed-batch method of making human anti-TNF-alpha antibody
Claim Types: Process
Humira (Injection) (Subcutaneous)8911737 Jun 5, 2022 Methods of administering anti-TNF.alpha. antibodies
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8911964 Sep 13, 2027 Fed-batch method of making human anti-TNF-alpha antibody
Claim Types: Process
Humira (Injection) (Subcutaneous)8916153 Apr 4, 2027 Purified antibody composition
Claim Types: Composition
Humira (Injection) (Subcutaneous)8926975 Jun 8, 2027 Method of treating ankylosing spondylitis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8961973 Apr 11, 2025 Multiple-variable dose regimen for treating TNF.alpha.-related disorders
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8961974 Apr 11, 2025 Multiple-variable dose regimen for treating TNF.alpha.-related disorders
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8974790 Jun 5, 2022 Methods of administering anti-TNF.alpha. antibodies
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8986693 Apr 11, 2025 Use of TNF.alpha. inhibitor for treatment of psoriasis
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8992926 Jun 5, 2022 Methods of administering anti-TNF.alpha. antibodies
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8999337 Feb 6, 2031 Methods for treating juvenile idiopathic arthritis by inhibition of TNF.alpha.
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9005926 Oct 1, 2030 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Tysabri (Injection) (Intravenous)9061005 Apr 11, 2025 Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)9062106 Apr 26, 2032 Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Claim Types: Process
Humira (Injection) (Subcutaneous)9067992 Jul 18, 2023 Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9085618 Mar 14, 2033 Low acidic species compositions and methods for producing and using the same
Claim Types: Formulation; Method of use
Humira (Injection) (Subcutaneous)9085619 Nov 28, 2028 Anti-TNF antibody formulations
Claim Types: Composition; Formulation
Humira (Injection) (Subcutaneous)9085620 Jul 18, 2023 Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis
Claim Types: Method of administration; Process
Humira (Injection) (Subcutaneous)9090688 Apr 26, 2032 Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Claim Types: Process
Humira (Injection) (Subcutaneous)9090689 Jul 18, 2023 Use of TNF.alpha. inhibitor for treatment of psoriasis
Claim Types: Method of administration; Process
Humira (Injection) (Subcutaneous)9090867 Sep 13, 2027 Fed-batch method of making anti-TNF-alpha antibody
Claim Types: Process
Humira (Injection) (Subcutaneous)9096666 Apr 4, 2027 Purified antibody composition
Claim Types: Formulation
Humira (Injection) (Subcutaneous)9096879 Jan 7, 2031 Method of supplementing culture media to prevent undesirable amino acid substitutions
Claim Types: Process
Tysabri (Injection) (Intravenous)9102723 Apr 4, 2027 Purified antibody composition
Claim Types: Process; Product-by-process; Method of use
Humira (Injection) (Subcutaneous)9109015 Aug 13, 2031 Method of isolating biomacromolecules using low pH and divalent cations
Claim Types: Process
Tysabri (Injection) (Intravenous)9150645 May 13, 2033 Cell culture methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)9181337 Mar 14, 2033 Modulated lysine variant species compositions and methods for producing and using the same
Claim Types: Formulation
Humira (Injection) (Subcutaneous)9181572 Mar 14, 2033 Methods to modulate lysine variant distribution
Claim Types: Process
Humira (Injection) (Subcutaneous)9187559 Apr 11, 2025 Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)9212379 Nov 28, 2030 Nutrient monitoring and feedback control for increased bioproduct production
Claim Types: Process
Tysabri (Injection) (Intravenous)9222106 Jun 4, 2028 Enhanced expression and stability regions
Claim Types: Cell; Process
Eylea (Injection) (Intravitreal)9234032 Sep 13, 2027 Fed-batch methods for producing adalimumab
Claim Types: Process
Humira (Injection) (Subcutaneous)9254338 May 22, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)9266949 May 13, 2033 Low acidic species compositions and methods for producing and using the same
Claim Types: Process
Humira (Injection) (Subcutaneous)9273132 Apr 4, 2027 Purified antibody composition
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9284370 Jun 10, 2028 Methods for treating juvenile idiopathic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9284371 Sep 13, 2027 Methods of producing adalimumab
Claim Types: Process
Humira (Injection) (Subcutaneous)9290568 Mar 14, 2033 Methods to control protein heterogeneity
Claim Types: Process
Humira (Injection) (Subcutaneous)9315574 Apr 21, 2033 Low acidic species compositions and methods for producing and using the same
Claim Types: Process
Humira (Injection) (Subcutaneous)9316641 Jan 9, 2032 Assay for JC virus antibodies
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)9328165 Apr 4, 2027 Purified antibody composition
Claim Types: Formulation
Humira (Injection) (Subcutaneous)9334319 Mar 14, 2033 Low acidic species compositions
Claim Types: Formulation claimed by its inherent performace characteristics
Humira (Injection) (Subcutaneous)9339610 Jan 24, 2032 Removal of needle shield from syringes and automatic injection devices
Claim Types: Device
Humira (Injection) (Subcutaneous)9346879 Mar 14, 2033 Protein purification methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)9359434 Mar 14, 2033 Cell culture methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)9441035 Apr 22, 2034 Cell culture media and methods of antibody production
Claim Types: Process
Avastin (Injection) (Intravenous)9487809 Jan 13, 2032 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Claim Types: Process
Avastin (Injection) (Intravenous)9493567 Mar 5, 2027 Methods of treating inflammatory and autoimmune diseases with natalizumab
Claim Types: Method of use
Tysabri (Injection) (Intravenous)9499614 Mar 14, 2034 Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
Claim Types: Process
Humira (Injection) (Subcutaneous)9499616 Mar 14, 2033 Modulated lysine variant species compositions and methods for producing and using the same
Claim Types: Process
Humira (Injection) (Subcutaneous)9505834 Apr 26, 2032 Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Claim Types: Process
Humira (Injection) (Subcutaneous)9512216 Apr 11, 2025 Use of TNF.alpha. inhibitor
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9522953 Apr 26, 2032 Low acidic species compositions and methods for producing and using the same
Claim Types: Drug in a container; Method of use
Humira (Injection) (Subcutaneous)9546212 Jun 5, 2022 Methods of administering anti-TNF.alpha. antibodies
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9550826 Nov 14, 2034 Glycoengineered binding protein compositions
Claim Types: Formulation
Humira (Injection) (Subcutaneous)9562252 May 11, 2033 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Tysabri (Injection) (Intravenous)9624295 Mar 31, 2031 Uses and compositions for treatment of psoriatic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9669069 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)9669093 Jun 10, 2028 Methods for treating juvenile idiopathic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9683033 Apr 26, 2032 Cell culture methods to reduce acidic species
Claim Types: Formulation; Method of use
Humira (Injection) (Subcutaneous)9688775 Dec 31, 2022 System for antibody expression and assembly
Claim Types: Process
Lucentis (Injection) (Intravitreal)9696307 Feb 5, 2030 Methods for the detection of JC polyoma virus
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)9708400 Mar 14, 2033 Methods to modulate lysine variant distribution
Claim Types: Formulation
Humira (Injection) (Subcutaneous)9709575 Apr 4, 2026 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)9714293 Aug 5, 2030 Production of proteins in glutamine-free cell culture media
Claim Types: Process
Avastin (Injection) (Intravenous)9765379 Mar 9, 2034 Harvest operations for recombinant proteins
Claim Types: Process
Lucentis (Injection) (Intravitreal)9790533 May 11, 2032 Methods of preventing and removing trisulfide bonds
Claim Types: Cell culture
Tysabri (Injection) (Intravenous)9795672 May 27, 2024 Treatment with anti-VEGF antibodies
Claim Types: Method of use
Avastin (Injection) (Intravenous)9816110 Oct 21, 2035 CHO integration sites and uses thereof
Claim Types: Cell; Process
Eylea (Injection) (Intravitreal)9856287 Jun 21, 2030 Refolding proteins using a chemically controlled redox state
Claim Types: Process
Neulasta (Injection) (Subcutaneous); Neulasta Onpro (Injection) (Subcutaneous)9913902 Apr 4, 2027 Purified antibody composition
Claim Types: Formulation claimed by its inherent performace characteristics
Humira (Injection) (Subcutaneous)9957318 Apr 26, 2032 Protein purification methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)9994968 Aug 19, 2034 Electrochemical etching apparatus
Claim Types: Process
Tysabri (Injection) (Intravenous)10011856 May 25, 2031 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Claim Types: Cell culture
Avastin (Injection) (Intravenous)10017732 Mar 13, 2034 Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Avastin (Injection) (Intravenous); Lucentis (Injection) (Intravitreal)10023831 Mar 17, 2035 Gas delivery devices and associated systems and methods
Claim Types: Device
Tysabri (Injection) (Intravenous)10112994 Nov 4, 2035 Methods of producing two chain proteins in bacteria
Claim Types: Process
Lucentis (Injection) (Intravitreal)10119976 May 27, 2034 Method of assessing risk of PML
Claim Types: Diagnostic or surgical method; Method of use
Tysabri (Injection) (Intravenous)10130681 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)10208355 Jul 13, 2035 Method of treatment for glioblastoma by administering a VEGF antagonist
Claim Types: Method of use
Avastin (Injection) (Intravenous)10233245 Feb 28, 2027 Methods of treating inflammatory and autoimmune diseases with natalizumab
Claim Types: Method of use
Tysabri (Injection) (Intravenous)10274466 Jul 10, 2035 Elucidation of ion exchange chromatography input optimization
Claim Types: Analytical procedure
Avastin (Injection) (Intravenous)10308706 Feb 5, 2032 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Tysabri (Injection) (Intravenous)10336983 Jul 30, 2035 Method for increasing the specific production rate of eukaryotic cells
Claim Types: Process
Avastin (Injection) (Intravenous)10406226 Mar 22, 2026 Method of manufacturing VEGF antagonist fusion proteins
Claim Types: Process
Eylea (Injection) (Intravitreal)10415055 Jun 4, 2028 Enhanced expression and stability regions
Claim Types: Cell; Process
Eylea (Injection) (Intravitreal)10421984 Sep 18, 2033 Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele
Claim Types: Process
Lucentis (Injection) (Intravitreal)10444234 Jan 11, 2031 Assay for JC virus antibodies
Claim Types: Diagnostic or surgical method; Device
Tysabri (Injection) (Intravenous)10464992 Jun 14, 2027 VEGF antagonist formulations suitable for intravitreal administration
Claim Types: Drug in a container; Formulation
Eylea (Injection) (Intravitreal)10513697 Sep 16, 2032 CO.sub.2 profile cultivation
Claim Types: Process
Avastin (Injection) (Intravenous)10590454 May 11, 2032 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Tysabri (Injection) (Intravenous)10662237 May 25, 2031 Method to improve virus filtration capacity
Claim Types: Process
Avastin (Injection) (Intravenous)10669594 Feb 12, 2037 Compositions and methods for detecting a biological contaminant
Claim Types: Analytical Method
Eylea (Injection) (Intravitreal)10676710 Mar 13, 2034 Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Avastin (Injection) (Intravenous)10676772 Aug 19, 2034 Control of protein glycosylation by culture medium supplementation and cell culture process parameters
Claim Types: Process
Tysabri (Injection) (Intravenous)10677803 May 27, 2034 Method of assessing risk of PML
Claim Types: Method of use
Tysabri (Injection) (Intravenous)10704071 Aug 17, 2031 Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Claim Types: Vector
Avastin (Injection) (Intravenous)10705095 Apr 4, 2026 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)10828345 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)10829732 Mar 13, 2034 Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Avastin (Injection) (Intravenous); Lucentis (Injection) (Intravitreal)10844416 Jan 6, 2036 Manganese supplementation for control of glycosylation in mammalian cell culture process
Claim Types: Process
Tysabri (Injection) (Intravenous)10857205 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)10857231 Disclaimer filed on March 14, 2022 Formulations of VEG antagonist fusion proteins and method of manufacturing them
Claim Types: Formulation; Formulation claimed by its inherent performace characteristics; Process
Eylea (Injection) (Intravitreal)10888601 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Dosaage regimen
Eylea (Injection) (Intravitreal)10905786 Mar 6, 2038 Sterilisation method
Claim Types: Process
Eylea (Injection) (Intravitreal)10906934 Oct 11, 2033 Protein purification methods
Claim Types: Process
Avastin (Injection) (Intravenous)10906986 Jul 7, 2028 Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Avastin (Injection) (Intravenous)10918754 Mar 6, 2038 Sterilisation method
Claim Types: Process
Eylea (Injection) (Intravitreal)10927342 Aug 3, 2036 Taurine supplemented cell culture medium and methods of use
Claim Types: Process
Eylea (Injection) (Intravitreal)10973879 May 17, 2039 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)10982003 Aug 6, 2030 Production of proteins in glutamine-free cell culture media
Claim Types: Process
Avastin (Injection) (Intravenous)11053280 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)11066458 Jun 14, 2027 VEGF antagonist formulations suitable for intravitreal administration
Claim Types: Drug in a container; Formulation
Eylea (Injection) (Intravitreal)11078294 Jul 8, 2028 Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Avastin (Injection) (Intravenous)11083792 Apr 4, 2027 Purified antibody composition
Claim Types: Formulation claimed by its inherent performace characteristics
Humira (Injection) (Subcutaneous)11084865 Jun 14, 2027 VEGF antagonist formulations suitable for intravitreal administration
Claim Types: Drug in a container; Formulation
Eylea (Injection) (Intravitreal)11104715 Aug 18, 2040 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Claim Types: Process
Eylea (Injection) (Intravitreal)11124760 Aug 27, 2035 Methods for overcoming glutamine deprivation during mammalian cell culture
Claim Types: Process
Tysabri (Injection) (Intravenous)11160918 Jul 29, 2039 Medical device packaging and related methods
Claim Types: Kit
Eylea (Injection) (Intravitreal)11167030 Nov 28, 2028 Protein formulations and methods of making same
Claim Types: Formulation
Humira (Injection) (Subcutaneous)11174283 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)11186625 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Composition; Product-by-process
Eylea (Injection) (Intravitreal)11191834 Nov 28, 2028 Protein formulations and methods of making same
Claim Types: Formulation
Humira (Injection) (Subcutaneous)11253572 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)11268119 Feb 21, 2036 Copper supplementation for control of glycosylation in mammalian cell culture process
Claim Types: Process
Tysabri (Injection) (Intravenous)11280794 May 27, 2034 Method of assessing risk of PML
Claim Types: Method of use
Tysabri (Injection) (Intravenous)11287423 Jan 11, 2031 Assay for JC virus antibodies
Claim Types: Formulation; Process
Tysabri (Injection) (Intravenous)11292845 Feb 28, 2027 Methods of treating inflammatory and autoimmune diseases with natalizumab
Claim Types: Method of use
Tysabri (Injection) (Intravenous)11299532 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)11306135 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Composition; Product-by-process
Eylea (Injection) (Intravitreal)11332771 Mar 14, 2034 Serum-free cell culture medium
Claim Types: Process
Eylea (Injection) (Intravitreal)11433186 Aug 18, 2040 Devices and methods for precision dose delivery
Claim Types: Device; Process
Eylea (Injection) (Intravitreal)11439758 Aug 18, 2040 Devices and methods for precision dose delivery
Claim Types: Device
Eylea (Injection) (Intravitreal)11459373 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)11459374 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)11472861 Aug 18, 2040 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Claim Types: Process
Eylea (Injection) (Intravitreal)D858754 Sep 3, 2034 Syringe cap
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)D906102 Dec 29, 2035 Packaging
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)D934069 Oct 26, 2036 Packaging
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)D961376 Aug 18, 2040 Packaging
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)D961377 Aug 18, 2040 Packaging
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)